Статті в журналах з теми "Immune-related adverse effects (irAEs)"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Immune-related adverse effects (irAEs)".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Naing, Aung, Joud Hajjar, James L. Gulley, Michael B. Atkins, Gennaro Ciliberto, Funda Meric-Bernstam, and Patrick Hwu. "Strategies for improving the management of immune-related adverse events." Journal for ImmunoTherapy of Cancer 8, no. 2 (December 2020): e001754. http://dx.doi.org/10.1136/jitc-2020-001754.
Повний текст джерелаReynolds, Kerry Lynn, Justine Vanessa Cohen, Sienna Durbin, Molly Thomas, Michael Dougan, Holly S. Martinson, Alex Faje, et al. "Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready?" Journal of Clinical Oncology 36, no. 5_suppl (February 10, 2018): 127. http://dx.doi.org/10.1200/jco.2018.36.5_suppl.127.
Повний текст джерелаChen, Ru, Min Zhou, and Feng Zhu. "Immune Checkpoint Inhibitors Related to Cardiotoxicity." Journal of Cardiovascular Development and Disease 9, no. 11 (November 3, 2022): 378. http://dx.doi.org/10.3390/jcdd9110378.
Повний текст джерелаKawahira, Machiko, Shuji Kanmura, Keiko Mizuno, Kentaro Machida, Takao Ohtsuka, Masami Sato, Hideki Enokida, et al. "Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events." PLOS ONE 17, no. 4 (April 28, 2022): e0267572. http://dx.doi.org/10.1371/journal.pone.0267572.
Повний текст джерелаWang, QuanQiu, and Rong Xu. "Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis." JAMIA Open 2, no. 1 (October 15, 2018): 173–78. http://dx.doi.org/10.1093/jamiaopen/ooy045.
Повний текст джерелаCoschi, Courtney H., and Rosalyn A. Juergens. "The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer." Current Oncology 28, no. 6 (November 2, 2021): 4392–407. http://dx.doi.org/10.3390/curroncol28060373.
Повний текст джерелаThapa, Bicky, Joanna Roopkumar, Ann S. Kim, Lorenzo Gervaso, Pradnya Dinkar Patil, Cassandra Calabrese, Alok A. Khorana, and Pauline Funchain. "Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e14151-e14151. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14151.
Повний текст джерелаKapoor, Akhil, Vanita Noronha, Vijay Maruti Patil, Amit Joshi, Nandini Sharrel Menon, and Kumar Prabhash. "Association of immune-related adverse effects and survival in responders treated with immune checkpoint inhibitors." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e15172-e15172. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e15172.
Повний текст джерелаRodriguez, Benigno, José Fabián Martínez-Herrera, Lorena López Zepeda, Guillermo Olivares, Alberto Villalobos, Fernando Perez, Christian Patricio Camacho Limas, et al. "Association of immune-related adverse events with immune-checkpoint inhibitors and treatment response in melanoma patients." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e21522-e21522. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21522.
Повний текст джерелаKim, Sarah, A. Dimitrios Colevas, Stephanie Tse, Sandy On, and Edna Cheung. "Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 2661. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.2661.
Повний текст джерелаMedina, Patrick, Kate D. Jeffers, Van A. Trinh, and R. Donald Harvey. "The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy." Journal of Pharmacy Practice 33, no. 3 (November 6, 2019): 338–49. http://dx.doi.org/10.1177/0897190019885230.
Повний текст джерелаMelia, A., E. Fockens, A. Madroszyk, P. Lafforgue, and T. Pham. "OP0278 MUSCULOSKELETAL IMMUNE-RELATED ADVERSE EVENTS IN 927 PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS FOR SOLID CANCER." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 184.1–185. http://dx.doi.org/10.1136/annrheumdis-2022-eular.252.
Повний текст джерелаVerspohl, Sophia H., Tobias Holderried, Charlotte Behning, Peter Brossart, and Valentin S. Schäfer. "Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis." Therapeutic Advances in Musculoskeletal Disease 13 (January 2021): 1759720X2110069. http://dx.doi.org/10.1177/1759720x211006963.
Повний текст джерелаZhang, Shuo, Ziyue Zhou, Li Wang, Mengtao Li, Fengchun Zhang, and Xiaofeng Zeng. "Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis." Therapeutic Advances in Chronic Disease 12 (January 2021): 204062232097699. http://dx.doi.org/10.1177/2040622320976996.
Повний текст джерелаBoruah, Abhilasha Pankaj, Kathryn Demski, Pradnya Dinkar Patil, Cassandra Calabrese, and Pauline Funchain. "Implementation and impact of a novel multidisciplinary immune-related adverse events tumor board for patients receiving immune checkpoint inhibitor therapy." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e13541-e13541. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e13541.
Повний текст джерелаZhang, You-Cheng, Tian-Chen Zhu, Run-Cong Nie, Liang-He Lu, Zhi-Cheng Xiang, Dan Xie, Rong-Zhen Luo, and Mu-Yan Cai. "Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors." Journal of Clinical Medicine 12, no. 3 (January 17, 2023): 736. http://dx.doi.org/10.3390/jcm12030736.
Повний текст джерелаHamatake, Kiyonori, and Kazuaki Kojima. "Initiatives for immune-related adverse events by the outpatient pharmacist clinic." Trends in Immunotherapy 6, no. 1 (January 10, 2022): 3. http://dx.doi.org/10.24294/ti.v6.i1.1385.
Повний текст джерелаWalker, Josh, Mena Farag, Debra Josephs, Victoria Williams, and Paul Holmes. "011 A case of a neurological immune-related adverse event associated with ipilimumab/nivolumab." Journal of Neurology, Neurosurgery & Psychiatry 93, no. 9 (August 12, 2022): e2.203. http://dx.doi.org/10.1136/jnnp-2022-abn2.55.
Повний текст джерелаGnanapandithan, Karthik, Prakash Kharel, Alyssa Grimshaw, and Smith Giri. "Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series." Blood 134, Supplement_1 (November 13, 2019): 3606. http://dx.doi.org/10.1182/blood-2019-132203.
Повний текст джерелаMorgado, Manuel, Ana Plácido, Sandra Morgado, and Fátima Roque. "Management of the Adverse Effects of Immune Checkpoint Inhibitors." Vaccines 8, no. 4 (October 1, 2020): 575. http://dx.doi.org/10.3390/vaccines8040575.
Повний текст джерелаGupta, Samir, Anas Belouali, Neil J. Shah, Michael B. Atkins, and Subha Madhavan. "Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine Learning." JCO Clinical Cancer Informatics, no. 5 (May 2021): 541–49. http://dx.doi.org/10.1200/cci.20.00109.
Повний текст джерелаWeinmann, Sophia C., and David S. Pisetsky. "Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors." Rheumatology 58, Supplement_7 (December 1, 2019): vii59—vii67. http://dx.doi.org/10.1093/rheumatology/kez308.
Повний текст джерелаNasca, Vincenzo, Francesco Barretta, Francesca Corti, Sara Lonardi, Monica Niger, Maria Elena Elez, Marwan Fakih, et al. "Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer." Journal for ImmunoTherapy of Cancer 11, no. 1 (January 2023): e005493. http://dx.doi.org/10.1136/jitc-2022-005493.
Повний текст джерелаCabanillas, Gerardo. "Immune related adverse events and their treatment in melanoma patients receiving ipilimumab." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e14598-e14598. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14598.
Повний текст джерелаKulkarni, Ajinkya, Mrunal Kulkarni, Vinay Edlukudige Keshava, Rithikaa Ellangovan, and Rajesh Thirumaran. "Awareness of immune-related adverse events among medical residents in a community hospital." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e15154-e15154. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e15154.
Повний текст джерелаWeber, Jeffrey S. "Practical Management of Immune-Related Adverse Events from Immune Checkpoint Protein Antibodies for the Oncologist." American Society of Clinical Oncology Educational Book, no. 32 (June 2012): 174–77. http://dx.doi.org/10.14694/edbook_am.2012.32.79.
Повний текст джерелаKalinich, Mark, William Murphy, Shannon Wongvibulsin, Vartan Pahalyants, Kun-Hsing Yu, Feicheng Wang, Leyre Zubiri, et al. "854 Prediction of severe immune-related adverse events in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the United States." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A907. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0854.
Повний текст джерелаStelmachowska-Banaś, Maria, and Izabella Czajka-Oraniec. "Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review." Endocrine Connections 9, no. 10 (October 2020): R207—R228. http://dx.doi.org/10.1530/ec-20-0342.
Повний текст джерелаTyan, Kevin, Joanna Baginska, Martha Brainard, Anita Giobbie-Hurder, Mariano Severgnini, Michael Manos, Rizwan Haq, et al. "648 Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A685—A686. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0648.
Повний текст джерелаLuo, Jia, Jason Beattie, Paige Fuentes, Hira Rizvi, Jacklynn V. Egger, Jeffrey Kern, Donald Y. M. Leung, et al. "Beyond steroids: Immunosuppressants in steroid-refractory/resistant immune related adverse events." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 9092. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9092.
Повний текст джерелаFa'ak, Faisal, Chrystia M. Zobniw, Maryam Buni, Linda Lu, Adewunmi Falohun, VanAnh Trinh, Muhammad Osama Awiwi, et al. "816 Selective immune suppression using interleukin-6 blockade in immune related adverse events." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A853. http://dx.doi.org/10.1136/jitc-2021-sitc2021.816.
Повний текст джерелаOu, Qiyun, Yunfang Yu, Haitao Zhong, Anlin Li, Yongjian Chen, HaiYu Zhou, Shaopeng Zheng, Luyu Huang, and Herui Yao. "Association of immune-related adverse events with immune checkpoint inhibitor efficacy in pancancer." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e14087-e14087. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14087.
Повний текст джерелаGandy, Nemi, Mubarik A. Arshad, Kathryn L. Wallitt, Suraiya Dubash, Sameer Khan, and Tara D. Barwick. "Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging." British Journal of Radiology 93, no. 1111 (July 2020): 20190832. http://dx.doi.org/10.1259/bjr.20190832.
Повний текст джерелаOffin, Michael, Jacklynn V. Egger, Caroline G. McCarthy, Vasilisa Rudneva, Jason Beattie, Michelle S. Ginsberg, Jennifer L. Sauter, et al. "Improved survival among patients with malignant pleural mesotheliomas who develop immune-related adverse events on immunotherapy." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 8556. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.8556.
Повний текст джерелаKozono, David E., Elad Sharon, Jennifer Le-Rademacher, Erin Twohy, Tyler J. Zemla, Yujia Wen, Mark Watson, et al. "Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): TPS3154. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps3154.
Повний текст джерелаPatwari, Anannya, Vineel Bhatlapenumarthi, Antoine Joseph Harb, and Adam Curtis. "Immune related adverse effects (IRAEs) in patients with cancer who received immune checkpoint inhibitors (ICIs): A single center experience from rural Maine." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e19265-e19265. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19265.
Повний текст джерелаBayless, Nicholas L., Jeffrey A. Bluestone, Samantha Bucktrout, Lisa H. Butterfield, Elizabeth M. Jaffee, Christian A. Koch, Bart O. Roep, et al. "Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR." Journal for ImmunoTherapy of Cancer 9, no. 9 (September 2021): e002627. http://dx.doi.org/10.1136/jitc-2021-002627.
Повний текст джерелаMorales-Barrera, Rafael, Cristina Suarez Rodriguez, Macarena Gonzalez, Javier Ros, Maria Eugenia Semidey, Ester Serra Hernandez, Joaquin Mateo, et al. "Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 4531. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4531.
Повний текст джерелаWeber, Jeffrey S., Katharina C. Kähler, and Axel Hauschild. "Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab." Journal of Clinical Oncology 30, no. 21 (July 20, 2012): 2691–97. http://dx.doi.org/10.1200/jco.2012.41.6750.
Повний текст джерелаBorówka, Maciej, Stanisław Łącki-Zynzeling, Michał Nicze, Sylwia Kozak, and Jerzy Chudek. "Adverse Renal Effects of Anticancer Immunotherapy: A Review." Cancers 14, no. 17 (August 23, 2022): 4086. http://dx.doi.org/10.3390/cancers14174086.
Повний текст джерелаLópez Gallego, Javier, Pablo Ayala de Miguel, Itziar Gorospe García, Pablo René Rivera Vargas, Andrea Posada Restrepo, Jonathan Aires Machado, Rubén Alonso Calderón, et al. "Immune-related adverse events and outcomes during treatment with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) patients." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e21662-e21662. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e21662.
Повний текст джерелаTarhini, Ahmad. "Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management." Scientifica 2013 (2013): 1–19. http://dx.doi.org/10.1155/2013/857519.
Повний текст джерелаMujumdar, Urvi, Huifen Wang, Elizabeth Lawler, Victoria Lanzarini, Maria Lowe, Nataliya Trunova, Alyssa B. Klein, and Cathy Emmas. "Immune-related adverse event (irAE) education, self-efficacy, and potential irAE experiences in patients treated with immunotherapy for non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 37, no. 8_suppl (March 10, 2019): 76. http://dx.doi.org/10.1200/jco.2019.37.8_suppl.76.
Повний текст джерелаChmielewska, Izabela, Marta Dudzińska, Michał Szczyrek, Joanna Świrska, Kamila Wojas-Krawczyk, and Agnieszka Zwolak. "Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?" PLOS ONE 16, no. 9 (September 29, 2021): e0257484. http://dx.doi.org/10.1371/journal.pone.0257484.
Повний текст джерелаInaba, Hidefumi, Hiroyuki Ariyasu, Hisako Okuhira, Yuki Yamamoto, Hiroaki Akamatsu, Masahiro Katsuda, Masatoshi Jinnin, Isao Hara, and Takashi Akamizu. "Endocrine dysfunctions during treatment of immune-checkpoint inhibitors." Trends in Immunotherapy 4, no. 1 (June 7, 2020): 18. http://dx.doi.org/10.24294/ti.v4.i1.606.
Повний текст джерелаCheung, Yee-Ming Melody, Wei Wang, Bradley McGregor, and Ole-Petter Hamnvik. "RF05 | PSUN354 Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors – A systematic review and meta-analysis." Journal of the Endocrine Society 6, Supplement_1 (November 1, 2022): A891—A892. http://dx.doi.org/10.1210/jendso/bvac150.1846.
Повний текст джерелаPatil, Pradnya Dinkar, Alexia Zagouras, Wei (Auston) Wei, and Nathan A. Pennell. "Incidence and patterns of immune related adverse events (irAEs) during chemoimmunotherapy (ChemoIO) in patients with advanced nonsquamous NSCLC." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e20705-e20705. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e20705.
Повний текст джерелаShore, Neal. "Diagnosis and Management of Checkpoint Inhibitor Side Effects in Patients with Bladder Cancer: the Urologist’s Perspective." Bladder Cancer 6, no. 4 (December 14, 2020): 425–33. http://dx.doi.org/10.3233/blc-200362.
Повний текст джерелаGrizzi, Giulia, Fausto Petrelli, Michele Ghidini, Antonio Ghidini, Margherita Ratti, Stefano Panni, Mary Cabiddu, et al. "Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e14130-e14130. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14130.
Повний текст джерелаPender, Lori Keys, Haleh Kadkhoda, Katie S. Lucero, Patti Repetto, Charlotte Warren, Jacqueline Gearhart, and Jeffrey S. Weber. "Effects of online education on the identification and management of immune-related adverse events over time." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e18224-e18224. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18224.
Повний текст джерела